600713.SH
南京医药
SSE · Healthcare · Medical - Distribution · CN
CNY 5.16
−0.77%Year over year
Reported trailing growth
- Revenue
- +1.1%
- EBITDA
- —
- EBIT
- +13.0%
- EPS
- +6.1%
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- +3.1%
- EBITDA
- +7.0%
- EBIT
- +7.5%
- Net income
- +1.6%
- EPS
- +0.3%
- Free cash flow
- —
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026